|Articles|July 1, 2002

FDA panel: Thumbs up on alefacept

Silver Spring, Md. - The FDA Dermatologic and Ophthalmic AdvisoryCommittee, by an 8-2 vote, on May 23 recommended approval of alefacept,a systemic drug for the treatment of chronic plaque psoriasis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

Common Mistakes in Managing Hair Loss and Pigmentary Disorders

ByOyetewa Asempa, MD, FAAD,Shannon Heaning, Content Associate

August 13th 2026

GPP Awareness Day: Flare Triggers and IL-36 Targeted Therapy With Spesolimab

ByAaron S. Farberg, MD,Kaitlyn Bader, Assistant Managing Editor

August 13th 2026

Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases

ByMarie Bosslett, Assistant Editor

August 13th 2026

GPP Awareness Day: Recognizing Severity Across Care Settings

ByAaron S. Farberg, MD,Kaitlyn Bader, Assistant Managing Editor

August 13th 2026

Addressing Treatment Hesitancy in Pediatric Psoriasis

ByEileen Cheever, MPAS, PA-C,Shannon Heaning, Content Associate

August 13th 2026

Latest CME

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

FDA panel: Thumbs up on alefacept

Related Content

Common Mistakes in Managing Hair Loss and Pigmentary Disorders

GPP Awareness Day: Flare Triggers and IL-36 Targeted Therapy With Spesolimab

Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases

GPP Awareness Day: Recognizing Severity Across Care Settings

Addressing Treatment Hesitancy in Pediatric Psoriasis

Latest CME

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Trending on Dermatology Times

Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease

Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine

Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension

Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases